How RFK Jr. Weaponizes Real Science to Make False Medical Claims

Summary

• Antipsychotic discontinuation leads to relapse in approximately 65% of schizophrenia patients within one year, compared to 27% who continue medication, with some studies showing 97-98% relapse rates after stopping long-acting injectable antipsychotics.
• Discontinuing antipsychotics is associated with increased mortality (suicide, cardiovascular, and all-cause), increased rehospitalization, and severe relapses that can cause brain damage, harm to self or others, and loss of employment or relationships.
• The Number Needed to Harm for relapse is just 5, meaning one additional relapse occurs for every 5 patients who discontinue medication—one of the largest drug effects documented in medicine.
• Only 6% of first-episode schizophrenia patients achieve sustained recovery over 10 years, and relapse risk remains elevated even after 3-7 years of continuous antipsychotic use before discontinuation.
• The article's limited emphasis on these discontinuation risks is problematic when discussing dietary alternatives promoted as potential 'cures,' as patients might be misled into abandoning proven treatments with near-certain severe consequences.

The Critical Context of Antipsychotic Discontinuation Risks

The article's claim about inadequate context regarding medication discontinuation risks is well-founded and represents a significant public health concern. The documented evidence shows that discontinuing antipsychotic medications for schizophrenia carries substantial and well-quantified risks that would be essential for readers to understand when evaluating dietary alternatives.

Relapse rates following antipsychotic discontinuation are alarmingly high. Antipsychotics reduce relapse rates from 65% to 27% within one year, representing one of the largest drug effects in medicine. When patients discontinue these medications, the Number Needed to Harm (NNH) for relapse is just 5, meaning one additional relapse occurs for every 5 patients who stop treatment. Two open non-randomized studies of long-acting injectable antipsychotics reported relapse rates of 98% and 97% following discontinuation.

Mortality and Hospitalization Consequences

Beyond relapse, discontinuation is associated with increased mortality. A nationwide 20-year follow-up study of 8,719 first-episode schizophrenia patients found that discontinuation of antipsychotic medication anytime during follow-up was associated with an increased hazard of both rehospitalization and death. Multiple large nationwide observational studies have documented that antipsychotic discontinuation is associated with increased relapse, rehospitalization, suicide mortality, cardiovascular mortality, and all-cause mortality.

Severity and Long-Term Impact of Relapses

The consequences of relapse extend far beyond temporary symptom return. Relapses following antipsychotic discontinuation vary in severity, with severe relapses resulting in harm to the patient or others, prolonged hospitalization, loss of employment or relationships, and cognitive decline. Evidence suggests that sudden withdrawal from antipsychotics may lead to rebound psychosis that is more severe than if the patient had never been treated. Multiple episodes of acute psychosis lead to poorer long-term outcomes, and acute psychosis causes damage to the brain.

Why This Context Matters for Dietary Claims

The article's lack of emphasis on these discontinuation risks becomes particularly problematic when juxtaposed against Kennedy's "cure" claims. In the article, Palmer describes two women who "stopped using antipsychotic medication and remain symptom-free years after starting ketogenic diets." While Palmer appropriately notes these patients needed to remain on their diets and that other patients did not have similar outcomes, the article doesn't quantify how exceptional these cases are against the backdrop of 97-98% relapse rates in discontinuation studies.

Only 6% of first-episode psychosis patients with schizophrenia achieved Early Sustained Recovery (remission within 6 months and no further psychotic episodes) over 10 years. Treatment-resistant schizophrenia occurs in 22.8% of first-episode psychosis cohorts. Higher relapse risk persists even in patients who have taken antipsychotics for 3–6 years before stopping medication in randomized trials, and for up to 7 years according to registry studies.

Abrupt withdrawal poses particularly severe risks. Numerous studies have shown that abrupt withdrawal of antipsychotics dramatically increases the risk of relapse. Most people with schizophrenia must stay on antipsychotics continuously for months, years, or indefinitely for mental wellness, as relapses typically occur when people stop taking prescribed medication or take it sporadically.

The Ethical Imperative of Complete Disclosure

Notably, antipsychotic discontinuation shows no improvements in social functioning, cognitive function, quality of life, or satisfaction compared to continued treatment—meaning patients who stop medication face increased risks without compensating benefits. Given these statistics, any public discussion of dietary alternatives that might lead patients to discontinue proven medications carries an ethical obligation to prominently feature these discontinuation risks, which the article addresses only tangentially through psychiatrists' general statements that schizophrenia is "managed and not cured."